Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antidepressant Therapy to Improve Vascular Function After Preeclampsia
NCT07715669Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, single-arm trial of paroxetine in preeclampsia and major depressive disorder (MDD). Primary endpoints: Microvascular endothelium-dependent dilation response at 4 hours and Nitric oxide-dependent dilation response at 4 hours. Started Aug 2026; status: recruiting.
02
Drugs
paroxetine
03
Conditions
preeclampsiamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07715669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07715669.